Congenital Abnormalities  >>  Zykadia (ceritinib)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zykadia (ceritinib) / Novartis
NCT01283516: A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

Checkmark ELCC 2015
Apr 2015 - Apr 2015: ELCC 2015
Checkmark For ALK+ NSCLC
May 2014 - Jun 2014: For ALK+ NSCLC
Checkmark ASCO 2014
More
Completed
1
304
Canada, US, Europe, RoW
LDK378
Novartis Pharmaceuticals
Tumors Characterized by Genetic Abnormalities of ALK
05/16
05/16

Download Options